|
| MicroRNA | Expression | Target/Function | Clinical value |
|
| | | |
| let-7 family | Down | HMGA2, RAS, Myc, cell division | Associated with cancer-specific mortality and disease-free survival; increased sensibility to radiation; elevated postoperative risk of death; rs712GG genotype in K-RAS 3′-UTR associated with increased risk of NSCLC |
| let-7a-2 | Down | — | Poor survival in AC patients |
| miR-17 | Up | cell proliferation | Associated with tumor stage, cancer-specific mortality, and disease-free survival in NSCLC |
| miR-102 | Up | — | Higher levels in AC than in SqCC |
| miR-125a-3p/5p | Down | — | Associated with tumor invasion and lymph node metastasis |
| miR-126 | Down | VEGF | — |
| miR-128b | Down | EGFR | Benefit in patients treated with gefitinib |
| miR-145 | Down | c-Myc, eIF4E4, CDK4 | — |
| miR-155 | Up | — | Associated with tumor stage, cancer-specific mortality, and disease-free survival in NSCLC |
| miR-196a2 | Up | — | rs11614913CC genotype associated with increased risk of lung cancer and reduced overall survival |
| miR-20b | Down | — | Associated with advanced stages and lymph node metastasis |
| miR-21 | Down | K-RAS, cell proliferation | Associated with tumor stage, cancer-specific mortality, and disease-free survival in NSCLC; able to discriminate lung cancer from healthy controls |
| miR-29s | Down | DNMT3A, DNMT3B | — |
| miR-205 | Up | — | Only detected in SqCC |
| miR-31 | Up | LATS2, PPP2R2A, cell proliferation | — |
| miR-328 | Up | cell migration | Associated with higher risk of brain metastasis development |
| | | Associated with overall survival |
| miR-451 | Down | RAB14, apoptosis | Associated with NSCLC stage, lymph node metastasis, and poor survival |
| miR-7 | Up | Ets2, cell proliferation | — |
| miR-92a-2* | Up | — | Chemoresistance and decreased survival of SCLC cases |
| miR-99b | Up | — | Higher levels in AC than in SqCC |
|
